Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
Status:
Completed
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
The primary objective of study is
- Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2
- Part B : To evaluate the proof of concept (POC) of GX-E2